Newsbenzinga
MapLight Therapeutics Autism Drug Shows Mixed Potential In Adolescents
· Published
Article summary
MapLight's ML-004 misses its main autism study goal but showed notable irritability improvements in adolescents.
An excerpt from the original article.
Comments —
Loading comments…